Recursion Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
RXRX Nasdaq 2836 www.recursion.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals (RXRX) Rises Higher Than Market: Key Facts - Jul 17th, 2025 3:50 pm
Recursion Pharmaceuticals Rises 6% in a Month: How to Play the Stock - Jul 17th, 2025 9:30 am
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? - Jul 16th, 2025 7:58 am
Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing - Jul 10th, 2025 3:50 pm
Morgan Stanley Assumes Coverage of Recursion Pharmaceuticals (RXRX) Stock with an Equal Weight Rating - Jul 9th, 2025 10:39 pm
Recursion Pharmaceuticals (RXRX) Rallies 8.7% on Hypophosphatasia - Jul 9th, 2025 12:22 pm
RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program - Jul 9th, 2025 9:56 am
Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M - Jul 9th, 2025 6:16 am
Sector Update: Health Care Stocks Advance Late Afternoon - Jul 8th, 2025 1:52 pm
Recursion Pharmaceuticals (RXRX) Drops on Profit-Taking - Jul 8th, 2025 12:30 pm
Sector Update: Health Care Stocks Advance in Afternoon Trading - Jul 8th, 2025 11:57 am
Here's Why Shares in Recursion Pharmaceuticals Surged Today - Jul 8th, 2025 11:28 am
Top Midday Gainers - Jul 8th, 2025 11:28 am
Update: Recursion, Rallybio Shares Rise After Deal on Joint Hypophosphatasia Candidate - Jul 8th, 2025 10:07 am
Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals - Jul 8th, 2025 6:00 am
Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia - Jul 8th, 2025 6:00 am
Why Recursion Pharmaceuticals (RXRX) Outpaced the Stock Market Today - Jul 3rd, 2025 3:50 pm
MS initiates coverage on AI Biotechs, flags key pipeline catalysts - Jul 3rd, 2025 6:35 am
MIT & Recursion Unveil Boltz-2, Accelerates Drug Discovery 1000x, Rivals Physics-Based Accuracy - Jun 30th, 2025 12:42 am
Why This Wildcard Stock Could Be a Future Star - Jun 28th, 2025 10:00 am